Dashboard
Manage Tickers

GLUE


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

dave--busters-entertainment-posts-downbeat-results-joins-adtran-holdings-and-other-big-stocks-moving-lower-in-tuesdays-pre-market-session
Dave & Buster's Entertainment Posts Downbe...
09/16/2025 13:02:27

why-webtoon-entertainment-shares-are-trading-higher-by-48-here-are-20-stocks-moving-premarket
Why Webtoon Entertainment Shares Are Tradi...
09/16/2025 09:41:12

Core News & Articles
12 Health Care Stocks Moving In Monday's I...
09/15/2025 17:06:06

monte-rosa-novartis-use-ai-powered-engine-to-advance-immune-disease-treatments
Monte Rosa, Novartis Use AI-Powered Engine...
09/15/2025 15:29:40

Monte Rosa's stock jumps as it partners with Novartis to develop degraders for immune diseases, with up to $5.7 billion in ...

Core News & Articles
12 Health Care Stocks Moving In Monday's P...
09/15/2025 12:10:36

Core News & Articles
Market-Moving News for Sept 15
09/15/2025 11:25:55

CHEK: 301% | MBody AI and Check-Cap Enter into Definitive Merger Agreement EVTV: 125% | Envirotech Unveils US-Made Heavy-Lift D...

monte-rosa-therapeutics-to-collaborate-with-novartis-to-develop-novel-degraders-for-immune-mediated-diseases
Monte Rosa Therapeutics To Collaborate Wit...
09/15/2025 11:04:23

Novartis receives an exclusive license to an undisclosed discovery targetNovartis also receives options to license two programs...

monte-rosa-therapeutics-q2-eps-015-beats-039-estimate-sales-2319m-beat-1080m-estimate
Monte Rosa Therapeutics Q2 EPS $(0.15) Bea...
08/07/2025 11:21:07

Monte Rosa Therapeutics (NASDAQ:GLUE) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate ...

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
07/22/2025 21:06:00

monte-rosa-announces-first-subjects-dosed-in-phase-1-study-evaluating-mrt-8102-nek7-directed-mgd-being-developed-for-treatment-of-inflammatory-conditions-driven-by-nlrp3-inflammasome-il-1-and-il-6-initial-results-from-phase-1-study-expected-in-h1-2026
Monte Rosa Announces First Subjects Dosed ...
07/21/2025 11:07:19

MRT-8102 Phase 1 study includes single and multiple ascending dose cohorts in healthy volunteers and is designed to evaluate sa...

monte-rosa-therapeutics--announces-the-publication-of-groundbreaking-new-discoveries-featured-on-the-cover-of-science-titled-mining-the-crbn-target-space-redefines-rules-for-molecular-glue-induced-neosubstrate-recognition
Monte Rosa Therapeutics Announces The Pub...
07/03/2025 18:16:52

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (M...

monte-rosa-therapeutics-advances-nek7-program-with-enhanced-cns-penetration-ind-filing-slated-for-2026
Monte Rosa Therapeutics Advances NEK7 Prog...
06/10/2025 11:07:09

In addition to MRT-8102, Monte Rosa is also working to advance a second-generation NEK7 program with enhanced CNS penetration w...

monte-rosa-therapeutics-plans-to-initiate-phase-1-study-of-mrt-8102-in-coming-weeks-and-anticipates-sharing-initial-results-in-h1-2026
Monte Rosa Therapeutics Plans To Initiate ...
06/10/2025 11:05:10

fda-clears-ind-application-for-monte-rosa-therapeutics-mrt-8102-nek7-directed-mgd-developed-to-treat-inflammatory-conditions-linked-to-nlrp3-il-1-and-il-6-dysregulation
FDA Clears IND Application For Monte Rosa ...
06/10/2025 11:04:34

MRT-8102, a highly selective NEK7-directed molecular glue degrader (MGD) developed to treat inflammatory conditions linked to N...

monte-rosa-therapeutics-q1-eps-057-beats-030-estimate-sales-8493m-beat-1425m-estimate
Monte Rosa Therapeutics Q1 EPS $0.57 Beats...
05/08/2025 11:24:02

Monte Rosa Therapeutics (NASDAQ:GLUE) reported quarterly earnings of $0.57 per share which beat the analyst consensus estimate ...

monte-rosas-mrt-51443-demonstrates-potent-cdk2-degradation-and-delays-resistance-to-cdk46-inhibitors-in-preclinical-studies
Monte Rosa's MRT-51443 Demonstrates Potent...
04/28/2025 11:03:54

CDK2 molecular glue degrader (MGD) in combination with CDK4/6 inhibition and anti-estrogen therapy achieved superior tumor regr...

wells-fargo-maintains-equal-weight-on-monte-rosa-therapeutics-lowers-price-target-to-10
Wells Fargo Maintains Equal-Weight on Mont...
03/21/2025 19:10:19

Wells Fargo analyst Derek Archila maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Equal-Weight and lowers the price t...

wedbush-maintains-outperform-on-monte-rosa-therapeutics-raises-price-target-to-17
Wedbush Maintains Outperform on Monte Rosa...
03/21/2025 14:25:44

Wedbush analyst Robert Driscoll maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Outperform and raises the price targe...

novartis-partner-monte-rosa-therapeutics-touts-positive-data-from-early-stage-study-of-investigational-drug-candidate-for-immune-mediated-disorders
Novartis Partner Monte Rosa Therapeutics T...
03/20/2025 18:30:51

Monte Rosa's MRT-6160 shows promising Phase 1 results, with Novartis backing its development in a deal that could reach $2....

monte-rosa-therapeutics-reports-q4-collaboration-revenue-of-60647m-exits-quarter-with-cash-and-equivalents-worth-377m
Monte Rosa Therapeutics Reports Q4 Collabo...
03/20/2025 11:17:10

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION